One of the forefront efforts at Sylvester is a newly launched clinical trial targeting high-grade neuroendocrine tumors (NETs). These aggressive malignancies present substantial therapeutic challenges due to their rarity and complex biological behavior, which have historically limited treatment advancements. Led by Aman Chauhan, M.D., director of the Neuroendocrine Tumor Program, the study explores an innovative therapeutic strategy combining immunotherapy with direct intratumoral injections of oncolytic viruses. This dual approach leverages the immune system’s ability to recognize and eradicate cancer cells while simultaneously utilizing virus-mediated oncolysis to disrupt tumor integrity. The trial heralds a fresh paradigm in NET management and aspires to set new standards for outcomes in this underserved patient population.

In the domain of kidney cancer, Sylvester researchers are elucidating the intricate metabolic pathways that define renal cell carcinoma (RCC), the predominant subtype of kidney cancer. Supported by a $400,000 Sylvester Team Science Award, a multidisciplinary team integrates molecular biology, clinical intervention, and nutrition science to dissect the metabolic dependencies that RCC exploits. Spearheaded by Tracy Crane, Ph.D., R.D.N., this work capitalizes on cutting-edge dietary interventions designed to modulate tumor metabolism and potentially circumvent adaptive resistance mechanisms. By unraveling these metabolic idiosyncrasies, the research promises to identify novel biomarkers and therapeutic targets, thus repositioning metabolic modulation at the heart of RCC treatment strategies.

Enhancing patient access to comprehensive cancer care remains a central aim for Sylvester, exemplified by the expansion of radiation oncology services at their Plantation campus. This 40,000-square-foot facility now offers a full spectrum of non-surgical oncologic therapies, providing residents of Broward County with streamlined access to advanced radiation treatments without the need to travel to the Miami main campus. As the region’s sole National Cancer Institute-designated cancer center, Sylvester’s decentralization of services underscores its dedication to patient-centered convenience, equity, and multidisciplinary collaboration in oncologic care delivery.

A landmark regulatory development has further transformed the landscape of multiple myeloma clinical research. In April 2024, an FDA advisory committee endorsed the use of minimal residual disease (MRD) as a surrogate endpoint amenable to accelerated drug approval pathways. MRD assesses the minute population of cancer cells persisting after treatment, offering a highly sensitive metric of therapeutic efficacy far beyond traditional response criteria. C. Ola Landgren, M.D., Ph.D., director of the Sylvester Myeloma Institute, was instrumental in advocating for this paradigm shift. His research rigorously validated MRD as a prognostic and predictive biomarker, setting the stage for expedited introduction of novel myeloma therapies predicated on molecular remission rather than conventional clinical endpoints.

On the frontier of computational biology, the Sylvester Comprehensive Cancer Center has unveiled an artificial intelligence (AI) model that proficiently predicts DNA methylation patterns—epigenetic modifications essential for controlling gene expression. Published in Science Advances, this work highlights how machine learning can decode the genome’s complex methylation landscape, pinpointing regulatory marks that dictate cellular identity and malignancy. Maria “Ken” Figueroa, M.D., associate director of translational research, emphasizes the critical importance of epigenetic profiling in distinguishing between benign and cancerous cells. This AI-driven insight holds transformative potential for diagnostics, prognostication, and the design of epigenetic therapies.

Understanding cancer’s metabolic demands extends beyond kidney malignancies to a broader biological inquiry into tumor cell “greed.” Priyamvada Rai, Ph.D., co-leader of Sylvester’s Tumor Biology Program, investigates how cancer cells’ voracious consumption of nutrients and metabolic rewiring create exploitable vulnerabilities. Her research delineates the biochemical pathways preferentially used by tumors—such as altered glucose and amino acid metabolism—and explores therapeutic interventions that disrupt these processes while sparing normal tissues. This metabolic exploitation strategy offers a paradigm shift in precision oncology, wherein therapeutic windows are defined by cancer-specific metabolic dependencies, minimizing collateral damage to healthy cells.

Collectively, Sylvester’s multifaceted initiatives illustrate the center’s leadership in integrating clinical innovation, molecular research, and patient-centered care. The proactive launching of novel trials, dietary metabolic interventions, expanded accessible services, regulatory science involvement, AI-enabled genomic mapping, and tumor metabolism exploration exemplify a comprehensive assault on cancer’s biological complexity. Each research thread complements the others, weaving a robust fabric of translational science that bridges laboratory findings directly to patient therapies.

The clinical trial combining immunotherapy with oncolytic viral vectors represents a particularly exciting frontier, as it seeks to harness two powerful modalities synergistically. Oncolytic viruses selectively infect and lyse cancer cells, releasing neoantigens that stimulate the host immune system. When paired with immune checkpoint inhibitors or other immunotherapeutics, this dual action can potentially elicit durable tumor regression even in refractory disease. Early data from this trial could revolutionize therapeutic algorithms for high-grade neuroendocrine cancers that currently lack effective systemic options, offering new hope to a historically underserved cohort.

Sylvester’s kidney cancer metabolic research is also pioneering, particularly through its innovative application of dietary modulation as a complement to molecular characterization. By manipulating nutrient availability, researchers aim to disrupt tumor-specific metabolic pathways, potentially sensitizing cancers to systemic agents or overcoming intrinsic resistance. This approach reflects an emerging field known as metabolic precision oncology, where patient-specific metabolic profiling may guide customized therapeutic regimens—akin to molecularly targeted therapies but focused on metabolic phenotypes.

The center’s expansion of radiation oncology services exemplifies an equally important focus on healthcare accessibility and system-level improvement. By offering comprehensive oncologic therapies in community-based settings, Sylvester minimizes logistical burdens for patients and fosters earlier intervention, adherence, and multidisciplinary collaboration. This strategic decentralization aligns with a growing recognition that effective cancer care depends as much on delivery infrastructure as on novel therapies.

The adoption of minimal residual disease as a clinical trial endpoint for multiple myeloma heralds broader implications for hematologic cancers. MRD’s sensitivity transforms response assessment from morphological to molecular levels, enabling more precise determination of disease eradication. This shift not only accelerates drug development but also informs clinical decision-making, such as therapy de-escalation or intensification based on MRD status. Sylvester’s pivotal role in these regulatory discussions underscores the importance of academic-industry-government partnerships in shaping future oncology standards.

In the genomic and epigenetic realm, the AI model mapping DNA methylation advances our ability to interpret the human genome’s functional regulation. Epigenetic alterations like methylation contribute substantially to oncogenesis by silencing tumor suppressor genes or activating oncogenes, but deciphering their genome-wide distribution and impact is challenging through conventional methods. Through machine learning, Sylvester scientists can now predict methylation landscapes with unprecedented accuracy, enabling new biomarkers for early detection and defining novel therapeutic targets within the epigenome.

Finally, the tumor metabolic research led by Dr. Rai addresses one of cancer’s most fundamental hallmarks: its altered metabolism. By dissecting how malignant cells exploit metabolic pathways differently from normal counterparts, this work promises interventions that can selectively starve tumors or impair their biosynthetic capabilities. Such strategies could synergize with existing chemotherapies and immunotherapies, constituting a new armory in oncologic precision medicine.

Sylvester Comprehensive Cancer Center’s April 2025 tip sheet encapsulates a holistic, forward-looking vision that integrates cutting-edge science with patient-centered care innovations. Through diverse yet interconnected research and clinical initiatives, the center not only pushes scientific boundaries but also ensures that discoveries translate into tangible benefits for patients across the cancer care continuum.

Subject of Research: High-Grade Neuroendocrine Tumors, Kidney Cancer Metabolism, Radiation Oncology Access Expansion, Minimal Residual Disease as a Clinical Endpoint in Multiple Myeloma, AI Prediction of DNA Methylation, Cancer Cell Metabolic Vulnerabilities.

Article Title: Sylvester Comprehensive Cancer Center Advances April 2025: Clinical Trials, Metabolism, AI, and More in Cancer Innovation

News Publication Date: April 2025

Web References:

• https://news.med.miami.edu/clinical-trial-opens-for-patients-with-high-grade-neuroendocrine-cancer/
• https://news.med.miami.edu/new-team-science-award-aims-to-unlock-mysteries-of-kidney-cancer/
• https://news.med.miami.edu/sylvester-comprehensive-cancer-center-plantation-expands-with-radiation-oncology/
• https://news.med.miami.edu/cancer-research-in-the-wake-of-a-key-fda-decision-on-minimal-residual-disease/
• https://news.med.miami.edu/ai-model-finds-marks-on-dna/
• https://news.med.miami.edu/q-and-a-with-cancer-researcher-priyamvada-rai-ph-d/

References:

• AI methylation study published in Science Advances: https://www.science.org/doi/10.1126/sciadv.adt4152

Image Credits: Photo by Sylvester Comprehensive Cancer Center

Keywords: Kidney cancer, Clinical trials, Food science, Clinical research, Artificial intelligence, Genomic DNA, DNA methylation, Multiple myeloma, Cancer research

Sophia Lunt, a prominent professor in biochemistry and molecular biology at MSU, along with her husband Richard Lunt, an esteemed professor in chemical engineering, have teamed up with Vincent Lavallo, a distinguished chemistry professor at UC Riverside. Together, they are pioneering the development of a new class of light-sensitive chemicals known as cyanine-carborane salts. These salts are intended for use in photodynamic therapy (PDT), a treatment modality that utilizes light to activate these agents to selectively eradicate metastatic breast cancer cells in laboratory mice.

This promising approach to cancer therapy addresses a critical medical need. Breast cancer, particularly in its aggressive forms, poses a significant challenge due to its propensity for metastasis—spreading cancer cells to other parts of the body. Traditional treatment methods can be harsh and often lead to debilitating side effects, leaving patients searching for safer alternatives. According to Dr. Sophia Lunt, the innovative cyanine-carborane salts offer a targeted treatment option that limits collateral damage to healthy tissue, enabling a more effective therapeutic window for patients facing limited treatment choices due to advanced disease.

The functioning of these advanced salts is central to their appeal. In standard PDT procedures, light-sensitive compounds are administered systemically, where they localize in cancer cells. Upon exposure to near-infrared light—light that is invisible to the naked eye but capable of penetrating tissues—these salts become activated, producing reactive species that effectively destroy cancer cells. This selective targeting allows for the sparing of adjacent healthy cells, thereby reducing the risk of adverse effects often seen in broader therapeutic approaches.

Current FDA-approved PDT agents suffer from significant limitations. They tend to linger in non-target tissues, notably in the skin, necessitating patients to avoid exposure to light for weeks after treatment. As articulated by Hyllana Medeiros, a postdoctoral researcher instrumental in the mouse studies, this limitation poses profound inconveniences for patients who must shield themselves from even dim light due to the risk of skin burns. The newly developed cyanine-carborane salts represent a pivotal advancement, as these innovative compounds are not only more effectively absorbed by cancer cells but also demonstrate a reduced propensity to remain within non-target tissues.

As the research team continues to refine these findings, they anticipate that the lessons learned from this work may catalyze broader applications in treating various other types of cancers. Amir Roshanzadeh, a graduate student at MSU and the primary author behind the recent publication detailing these findings, has noted that the research serves as a springboard for potential breakthroughs in targeted drug delivery systems. They envision a landscape where therapies could not only target breast cancer but also be adapted for other malignancies, creating a versatile framework for cancer treatment innovations.

The collaborative spirit that underpins this research underscores the necessity of interdisciplinary approaches in tackling complex health issues such as cancer. Richard Lunt emphasized the significance of melding diverse expertise from fields such as cancer biology, chemistry, and materials science engineering. It is through this collaborative effort that groundbreaking solutions emerge, designed to overcome the multifaceted challenges posed by cancer and improve patient outcomes.

The researchers’ innovative cyanine-carborane salts have already shown promising results in preclinical models, suggesting that this new therapy could soon transition into clinical trials. The ability to treat aggressive breast cancer more safely and effectively represents a critical advancement in oncology. As science moves forward, the hope is that these findings will resonate within the medical community, ultimately facilitating real-world applications that enhance patient care and expand therapeutic horizons.

As they stand on the cusp of significant advancements, the MSU researchers are compiling their findings for publication, adding to the vast repository of scientific literature essential for informing future research directions and clinical applications. The peer-reviewed article detailing their innovative research is expected to be published in "Angewandte Chemie," a revered journal within the chemical sciences community, further validating the significance of their work within the scientific literature.

The implications of their findings extend beyond just treatment for breast cancer; the techniques and insights gained through this research may provide a template for the development of future cancer therapies. It is a testament to the power of cooperative science, where diverse backgrounds and expertise converge to address urgent health dilemmas. The prospect of improving treatment modalities and extending the lives of cancer patients is a unifying goal that drives this team as they look to the future.

In conclusion, the pioneering work of this research team serves as a beacon of hope for the future of cancer treatment. The development of cyanine-carborane salts not only reflects a significant leap in photodynamic therapy but also embodies the collaborative spirit essential for scientific progression. Through continued research and innovation, the team aims to transform the landscape of oncological care, fostering a healthier, more hopeful future for individuals facing aggressive cancer diagnoses.

Subject of Research: Development of light-activated cyanine-carborane salts for photodynamic therapy targeting aggressive breast cancer.
Article Title: Next-Generation Photosensitizers: Cyanine-Carborane Salts for Superior Photodynamic Therapy of Metastatic Cancer
News Publication Date: 22-Jan-2025
Web References: Michigan State University
References: DOI: 10.1002/anie.202419759
Image Credits: Not provided.
Keywords: Photodynamic therapy, cancer treatment, breast cancer, cyanine-carborane salts, MSU, interdisciplinary research.